Ovarian cancer·• Cisplatin resistance • microRNA • Methylation • Epithelial-mesenchymal transition Abstract Background: Many microRNAs (miRs) are dysregulated in cancers, and aberrant miR expression patterns have been suggested to correlate with chemo-resistance of cancer cells. We aim to study the role of miR-30 family members in cisplatin-resistance of ovarian cancer cells. Methods: qRT-PCR was used to compare differential expression levels of miR-30 family members in ovarian cancer cell line A2780 and its cisplatin-resistant derivative CP70. Changes of cisplatin-sensitivity in miR-30a-5p-and miR-30c-5p-overexpressed-CP70 cells and miR30a-5p-and miR-30c-5p-inhibited-A2780 cells were examined by CCK8 assay and apoptosis analysis using flow cytometry; targets of miR-30a/c-5p were analyzed by western blotting and luciferase reporter assay; methylation regulation of pre-miR-30a/c-5p was examined by methylation specific PCR. Results: miR-30a-5p and miR-30c-5p, in contrast to other miR-30 family members, dramatically decreased in cisplatin-resistant CP70 cells due to overexpressed-DNMT1 induced aberrant methylation. miR-30a/c-5p in turn directly inhibited DNMT1 as well as Snail. Forced expression of miR-30a/c-5p or knocking down of DNMT1 and Snail promoted cisplatin susceptibility and partially reversed epithelial-mesenchymal transition (EMT) in CP70 cells, while inhibition of miR-30a/c-5p or ectopic expression of DNMT1 and Snail induced cisplatin resistance and partial EMT in cisplatin-sensitive A2780 cells. Conclusions: A feedback loop between miR-30a/c-5p and DNMT1 is a potent signature for cisplatin-resistance and EMT in ovarian cancer, promising a potential target for improved anti-cancer treatment.
Plasmid transfection
The human DNMT1 and Snail expression vectors were obtained from Addgene. Cells were seeded into 6-well plates until 70 %-80 % confluence and transiently transfected with 2 μg plasmids or empty vector using the X-treme GENE HP DNA Transfection Reagent (Roche, Indianapolis, IN, USA). After 24 h of transfection, the cells were treated with cisplatin for another 24 h.
siRNAs and miRs transfection
Knockdown of DNMT1 and Snail were performed using specific siRNAs purchased from GenePharma Company (Shanghai, China). Sequences of siRNAs are as follows: siDNMT1-a, 5'-UCUGUCCGUUCACAUGUGUdTdT-3'; siDNMT1-b, 5'-GGAUGAGAAGAGACGUAGAdTdT-3'; siSnail-a, 5'-GCGAGCUGCAGGACUCUAAUCdTdT-3'; siSnail-b,5'-AAUGCUCAUCUGGGACUCUGUdTdT-3'. A scrambled siRNA (5'-GCGACGAUCUGCCUAAGAUdTdT-3') was used in parallel experiments as negative control. miR30a/c-5p mimics or inhibitors and corresponding negative control were purchased from Ribo-Bio Co. Ltd. (Guangzhou, China). Cells were seeded into 6-well plates to reach 40%-50% confluence after 24 h and then transiently transfected with 5 μg siRNA, or 80 nM miR-30a/c-5p mimics, or 150 nM inhibitors and corresponding negative control using the X-treme GENE siRNA Transfection Reagent (Roche, Indianapolis, IN, USA). After 24 h of transfection, the cells were treated with cisplatin for another 24 h.
Cell viability assay
Cells were seeded (8×10 3 per well for A2780, 1×10 4 per well for CP70) in triplicates in 96-well plates. Cell viability was monitored using the cell counting kit-8 (CCK-8) assay (7seapharmtech Co., Ltd., Shanghai, China) after 24h-transfection followed by 24h-cisplatin treatment according to the manufacturer's instructions.
Apoptosis analysis
Apoptotic cells were detected using an Annexin V-PE/7-AAD apoptosis Detection Kit (BD Biosciences, Bedford, MA, USA) according to the manufacturer's instructions. Briefly, cells were washed with ice-cold PBS twice and stained with 100 μl of 1× binding buffer containing 5 μl PE Annexin V and 5 μl 7-AAD for 15 min at room temperature in the dark. Then 400μl of 1× binding buffer was added to each tube. Flow cytometry was performed to detect cellular apoptosis within 1 h, and the results were analyzed using the Cell-Quest TM Pro software (BD Biosciences, Bedford, MA, USA).
Quantitative real-time PCR (qRT-PCR)
Total cellular RNA was extracted using the Trizol reagent (Invitrogen; Carlsbad, CA, USA) according to manufacturer's instruction. Total RNA concentration was quantified by absorbance at 260 nm using spectrophotometer. 1 ng of total RNA was subjected to reverse transcription using the PrimeScript TM RT reagent Kit with gDNA Eraser (Takara; Dalian, China) according to the manufacturer's instructions. Each cDNA generated was amplified by quantitative PCR using SYBR Premix Ex Taq™ II kit (Takara; Dalian, China) on a CFX96 real-time PCR system (Bio-Rad; Hercules, CA, USA). The coding genes were normalized to β-actin, while miR-30s were normalized to small nuclear U6. The expression levels were automatically quantified using 2 -ΔΔCt . The primers for the coding genes were synthesized by Beijing Genomics Institute (Beijing, China), and the primer sequences were listed below: DNMT1 forward: 5'-CCTGAGGCCTTCACGTTCAA-3'; DNMT1 reverse: 5'-ACTTGTGGGTGTTCTCAGGC-3'; Snail forward: 5'-TCCAGAGTTTACCTTCCAGCA-3'; Snail reverse: 5'-CTTTCCCACTGTCCTCATCTG-3'; β-actin forward: 5'-TCCCTGGAGAAGAGCTACGA-3'; β-actin reverse: 5'-AGCACTGTGTTGGCGTACAG-3'. The primers for miR-30a-, 30b-, 30c-, 30d-and 30e-5p, and U6 reverse transcription and amplification were designed and synthesized by Ribo-Bio Co. Ltd. (Guangzhou, China).
Western blotting
Cell pellets were lysed in RIPA buffer containing 1 mM PMSF and 1% complete protease inhibitor cocktail (Roche Applied Science; Indianapolis, IN, USA). After quantification, equal amounts of lysate were separated by SDS-PAGE and then transferred onto NC membranes (Pall Life Science, Port Washington, NY, USA). Membranes were blocked in 5% nonfat milk and incubated with anti-DNMT1(1:1000, Active Motif; Carlsbad, CA, USA), anti-E-cadherin(1:1000, Cell Signaling Technology; Beverly, MA, USA), antivimentin(1:1000, Cell Signaling Technology; Beverly, MA, USA), anti-Snail(1:400, Cell Signaling Technology; Beverly, MA, USA), and anti-β actin (1:1000, Cell Signaling Technology; Beverly, MA, USA) primary antibodies, followed by incubation with goat-anti-rabbit or goat-anti-mouse secondary antibody conjugated with horseradish peroxidase (HRP) (1:2000, Pierce; Rockford, IL, USA). The protein signals were visualized using enhanced chemiluminescence reagents (Millipore, Billerica, MA, USA) by a chemiluminescence imaging system (Bio-Rad, Richmond, CA, USA).
Methylation specific PCR (MSP)
DNA bisulfite modification and purification were performed using an EZ DNA methylation-Direct kit (Zymo Research Corporation, Irvine, California, USA) according to the instruction. Concentration of DNA was evaluated by absorbance at 260 nm on a UV spectrophotometer (BioRad Inc., Hercules, CA, USA). The sets of primers for miR-30a/c-5p gene were flanking the 3kb regions of the 5' upstream regions from the start of premiR-30a/c-5p sequences. The primers for methylation-specific PCR were designed by MethPrimer and the sequences were as follows: 
Plasmids construction and Luciferase reporter assay
The 3' UTR of human DNMT1 gene containing predicted miR-30a/c-binding site was amplified by PCR from cDNA of CP70 cells using the following primers: forward (wt-F):
5'-CCCAAGCTTGGGGTCACCCCTGTTTCTGGCA-3'; and reverse (wt-R): 5'-CGAGCTCGCAAGGCCACAAACACCATGT-3'. The PCR products were digested with Hind III and Sac I enzymes and inserted into pMIR-REPORTTM Luciferase vectors (Ambion; Austin, TX, USA) to construct a DNMT1 WT-3' UTR vector. The transversion mutant in the miR-30a/c-5p seed region was generated by overlap extension method to construct DNMT1 MUT-3' UTR vector, and the primers were listed as follows: mu1 forward (mu1-F, containing the mutant first binding site): 5'-CCCAAGCTTGGGGTCACCCCGTGGGCTGGCACC-3'; mu2 forward (mu2-F, containing the second binding site): 5'-ACTGATGTTGGTGGGTTAACATGTC-3'; mu2 reverse (mu2-R, containing the second binding site): 5'-GACATGTTAACCCACCAACATCAGT-3'; mu3 reverse (mu3-R, containing the third binding site): 5'-CGAGCTCG CAAGGCCACCCCACCCATGTACC-3'. All the construct sequences were confirmed by sequencing. Snail WT-3' UTR and MUT-3' UTR vectors were constructed as previously reported [33] .
To perform luciferase reporter assay, cells grown in a 24-well plate were contransfected with 180 ng of recombinant wild-type (WT-3' UTR) or mutation (MUT-3' UTR) reporter vectors, 20 ng of pRL-TK vector and 20 nM miR mimics using X-treme GENE siRNA Transfection Reagent (Roche, Indianapolis, IN, USA). 24 h after transfection, cells were harvested, and reporter assays were performed using a dual-luciferase reporter gene assay system (Promega, Madison, WI, USA) according to the manufacturer's instructions. Luciferase activity was measured on the GloMax® 20/20 Luminometer (Promega, Madison, WI, USA).
Statistical analysis
The graphical presentations were prepared using GraphPad Prism 5.0. Data were presented as the means±SD and were analyzed using SPSS 22.0 software (Chicago, IL, USA). Statistical differences were analyzed by Chi-square test, or two-tailed t-test using SPSS software (Chicago, IL, USA). Differences were considered significant at P<0.05 (*) and highly significant at P<0.01 (**) for all comparison.
Results

miR-30a/c-5p reduction enhanced cisplatin resistance of ovarian cancer cells
We first compared A2780 and CP70 cells with respect to their resistance to cisplatin. The IC50 values for A2780 and CP70 cells treated by cisplatin were 21.92 and 206.0 μM, respectively (Fig. 1A) . 100 μM of cisplatin rendered a 2-fold increase in apoptosis of A2780 cells compared with CP70 cells (Fig. 1B) . The level of miR-30s in cisplatin-sensitive A2780 cells and cisplatin-resistant CP70 cells was then examined. Of the five members of the miR-30 family, only miR-30a/c-5p displayed a drastic reduction of more than 60% in CP70 cells relative to A2780 cells, while a moderate 30% decrease in the level of miR-30d and no significant change of miR-30b and -30e were observed under the same conditions (Fig. 1C) . ) qRT-PCR displayed 2000-and 300-fold increase in miR-30a-5p and miR-30c-5p, respectively, in miR-30a/c-5p mimics transfected-CP70 cells. (E) CCK8 assays showed that overexpression of miR-30a/c5p suppressed CP70 cell survival under cisplatin treatment and that mimics of miR-30a-5p and miR-30c-5p could synergistically sensitize CP70 cells to cisplatin. The IC50 values for negative control cells, miR-30a-5p mimic, miR-30c-5p mimic and miR-30a+c mimic-transfected CP70 cells were 237.6, 112.1, 104.3 and 78.36 μM, respectively. (F) Flow cytometry analysis showed that transfection by miR-30a-5p mimic and/ or miR-30c-5p mimic significantly increased apoptotic cell counts in CP70 cells, with the combination of miR-30a+c mimic being most effective. (G) qRT-PCR results showed the downregulation of miR-30a/c-5p via transfection of theirs inhibitors into A2780 cells. (H) CCK8 assays showed that downregulation of miR30a/c-5p increased cisplatin resistance of A2780 cells. The IC50s for negative control cells, miR-30a-5p inhibitor, miR-30c inhibitor and miR-30a+c inhibitors-transfected A2780 cells were 36.38, 58.99, 51.98 and 58.09 μM, respectively. (I) Flow cytometry analysis showed that inhibition of miR-30a/c-5p significantly suppressed cell apoptosis in A2780 cells where miR-30a/c-5p functioned synergistically. All experiments were carried out in triplicate and the results were presented as means ± SD. Calculation of statistical significance was performed using a two-tailed t-test.
The effects of miR-30a/c-5p on cisplatin resistance were further investigated. Forced expression of miR-30a/c-5p (Fig. 1D ) sensitized CP70 cells to cisplatin, as shown by a significant reduction in IC50 values (Fig. 1E ) and an increase in apoptotic cell counts (Fig.  1F ) in miR-30a/c-5p mimics-transfected CP70 cells compared with negative control cells. Of note, synergistic effects of miR-30a/c-5p mimics on cisplatin sensitivity were observed in CP70 cells (Fig. 1E and 1F ). By contrast, suppression of miR-30a/c-5p (Fig. 1G ) substantially enhanced cell survival (Fig. 1H ) and reduced cell apoptosis (Fig. 1I ) in cisplatin-treated A2780 cells. Similarly, miR-30a and miR-30c inhibitors were also synergistic on apoptosis as observed by flow cytometry. CCK8 results showed that Snail overexpression partly reversed the inhibitory effect of miR-30c-5p on cisplatin resistance of CP70 cells. The statistical differences were calculated using a two-tailed t-test.
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miR-30a/c-5p directly inhibited Snail to attenuate cisplatin resistance
Snail was predicted by TargetScan (http://www.targetscan.org/) and previously verified as a direct target of miR-30s. We therefore examined the association of miR-30a/c-5p with Snail as well as the role of Snail in cisplatin resistance. As shown in Figure 2A , the protein level of Snail was higher in CP70 cells than in A2780 cells. However, Snail protein decreased in miR-30a/c-overexpressed CP70 cells (Fig. 2B ) and increased in miR-30a/c-underexpressed A2780 cells (Fig. 2C) . A direct suppression of miR-30a/c-5p on Snail expression was further verified using luciferase reporter assay. Compared with the negative control, miR-30a/c-5p significantly diminished the luciferase activity of wild-type Snail 3' UTR, whereas it had no effect on that of a mutated Snail 3' UTR (Fig. 2D) . As expected, knocking down of Snail (Fig. 2E ) sensitized CP70 to cisplatin-induced cell death ( Fig. 2F and 2G) , while ectopic expression of Snail (Fig. 2H) promoted cisplatin-resistance in A2780 cells (Fig. 2I and 2J) . Furthermore, the activity of miR-30a/c-5p mimics on cisplatin sensitization was antagonized by concomitant overexpression of Snail in CP70 cells (Fig. 2K and 2L ). These data verified that miR-30a/c-5p directly suppressed Snail expression and consequently enhanced cisplatin sensitivity.
miR-30a/c-5p negatively regulated EMT
Since Snail, the direct target of miR-30a/c-5p, is a key pro-EMT factor, we examined the effect of miR-30a/c-5p on the expression pattern of EMT markers. CP70 cells displayed a comparable level of E-cadherin and a higher level of vimentin relative to A2780 cells (Fig. 3A) as well as an increased capability of migration (Fig. 3B) , indicating occurrence of partial EMT in CP70 cells. Overexpression of miR-30a/c-5p in CP70 cells decreased vimentin (Fig. 3C ) and inhibited cell migration (Fig. 3D) , while under-expression of miR-30a/c-5p in A2780 cells increased vimentin (Fig. 3E ) and promoted cell migration (Fig. 3F) . These data suggested that miR-30a/c-5p inhibited Snail to not only weaken cisplatin resistance but also reverse EMT. 
miR-30a/c-5p was downregulated by DNMT1-maintained methylation
Next, we investigated the mechanism responsible for miR-30a/c-5p reduction in cisplatin-resistant CP70 cells. Since potential methylation sites in the promoter region of miR-30a/c-5p precursor genes were found using online software (http://www.urogene. org/methprimer/), we studied the contribution of methylation regulation to the underexpression of miR-30a/c-5p in CP70 cells. When CP70 cells were treated with the DNA methylation inhibitor 5-Aza-dC, both miR-30a-5p and miR-30c-5p were elevated by more than 3-fold (Fig. 4A) . Methylation specific PCR (MSP) assay showed that methylation levels in the promoter regions of miR-30a/c-5p precursor genes were increased in CP70 cells (Fig.  4B) . A much higher level of the maintenance methyltransferase DNMT1 was detected in CP70 cells than in A2780 cells (Fig. 4C) .
The relationship of DNMT1 with miR-30a/c-5p in the occurrence of cisplatin resistance was therefore further studied. Knocking down of DNMT1 (Fig. 4D ) increased mRNA level of miR-30a/c-5p (Fig. 4E) and decreased the methylation levels of promoter regions in the miR-30a/c-5p precursor gene (Fig. 4F) . Ectopic expression of DNMT1 (Fig. 4G) repressed miR-30a/c-5p (Fig. 4H) and elevated the methylation levels in the promoters of miR30a/c-5p precursor genes (Fig. 4I ) in A2780 cells. These data demonstrated that DNMT1 downregulated miR-30a/c-5p via maintaining high levels of methylation in the promoter regions of miR-30a/c-5p precursor genes. 
DNMT1 contributed to cisplatin resistance and partial EMT
Since DNMT1 reversely regulated miR-30a/c-5p, the influence of DNMT1 on cisplatin resistance and EMT was then examined. Inhibition of DNMT1 sensitized CP70 cells to cisplatin as shown by decreased cell survival (Fig. 5A ) and increased cell apoptosis (Fig. 5B) under cisplatin pressure. Overexpression of DNMT1 introduced resistance to cisplatin in A2780 cells as illustrated by improved cell survival (Fig. 5C ) and reduced cell apoptosis (Fig. 5D) . Additionally, knocking down of DNMT1 in CP70 cells depressed vimentin expression (Fig.  5E ) and cell motility (Fig. 5F ), while ectopic expression of DNMT1 in A2780 cells enhanced vimentin expression (Fig. 5G) , and augmented cell migration (Fig. 5H) . These data indicated that DNMT1 promoted cisplatin resistance and partial EMT in ovarian cancer cells.
miR-30a/c-5p directly inhibited DNMT1
We investigated the possible effect of miR-30a/c-5p on DNMT1 expression as well, and found loss of DNMT1 in miR-30a/c-overexpressed CP70 cells (Fig. 6A) and gain of DNMT1 in miR-30a/c-underexpressed A2780 cells (Fig. 6B) . Although DNMT1 was not predicted as a miR-30s target by online miR target prediction tools, we manually located three potential (H) In vitro migration assay showed that cell motility was enhanced in DNMT1-overexpressed A2780 cells (original magnification ×400). The statistical differences were calculated using a two-tailed t-test.
binding sites of miR-30a/c-5p in the 3'UTR of DNMT1 (Fig. 6C) . Luciferase reporter assay demonstrated a direct suppression of miR-30a/c-5p on DNMT1 expression. Compared with the negative control, miR-30a/c-5p mimics significantly diminished the luciferase activity of wild-type DNMT1 3' UTR, whereas it had no effect on that of the mutated DNMT1 3' UTR (Fig. 6D) .
Discussion
Cisplatin is a mainstay of treatment for many solid tumors including ovarian cancer [34] . However, its clinical efficiency is frequently influenced by the onset of chemoresistance of tumor cells to cisplatin [35] . Overcoming cisplatin resistance necessitates the elucidation of the molecular determinants refractory to cisplatin. Recently, miR-30s have been found involved in the regulation of cisplatin-sensitivity of some cancers, where individual members of the miR-30 family assist tumor cells in both cisplatin re-sensitization [36, 37] and cisplatin insensitivity [38, 39] . Indeed, the inconsistency on the role of miR-30a/c-5p in tumor cell sensitivity to other chemo-therapeutics also exists in various cancers. For example, miR-30a-5p was inversely correlated with gemcitabine [40] and paclitaxel [41] sensitivity, while high expression of miR-30a/b/c-5p was resistant to gemcitabine in CD133+ pancreatic cancer stem-like cells [42] . Here, the downregulation of miR-30a/c-5p was found in cisplatin-resistant ovarian cancer cells, and miR-30a/c-5p overexpression re-sensitized cells to cisplatin. Of note, upregulation of miR-30a-5p by transfection of its mimic not only increased itself by more than 1500-fold but also increased miR-30e-5p to 100-fold (data not shown). Since miR-30a mimics predominantly enhanced miR-30e, and A2780 and CP70 cells expressed comparable level of miR-30e-5p, the effect of miR-30a-5p mimic on miR-30e-5p was considered to be insignificant in cisplatin resistance.
The regulatory mechanisms responsible for miR-30s downregulation in cisplatinresistant cancers remain largely unresolved. Reported studies have revealed the involvement of miRs and their epigenetic regulation in the development of chemoresistance [43] . Methylation of DNA at cytosine residues is an epigenetic modification critical for the regulation of gene expression [44, 45] . Mammalian DNA methyltransferase DNMT1 functions as a maintenance methyltransferase that is overexpressed [46] and hyperactivated [47] in many cancers, resulting in hypermethylation of promoter CpG islands and gene silence. Since DNMT1 promotes cisplatin-resistance [48, 49] , we examined the connection between miR-30a/c-5p and DNMT1 in the onset of cisplatin-resistance of ovarian cancer cells, and established a feedback loop between DNMT1 and miR-30a/c-5p as shown in Fig. 6E . Upregulated DNMT1 in cisplatin-refractory CP70 cells epigenetically attenuated miR-30a/ c-5p via methylating CpG-rich regions at the promoter regions of miR-30a/c-5p precursor genes, which blocked the inhibitory effect of miR-30a/c-5p on DNMT1 expression. Although DNMT1 was previously found to induce miR-30b promoter methylation and downregulate miR-30b [50] , DNMT1 was directly targeted by some miRs involved in ovarian cancer cisplatin resistance [51] . Our data revealed the existence of the feedback loop between miR-30a/c5p and DNMT1 which was first related to the cisplatin-resistance of ovarian cancer cells. Of note, miR-30s can be repressed via various mechanisms, as illustrated by the findings that miR-30s downregulation could be induced by hypoxia in a hypoxia-inducible factors dependent manner [52] , oncogenic signals such as epidermal growth factor and hepatocyte growth factor, or competitive endogenous RNA [53] . Our observation provided an additional regulatory pathway controlling miR-30s expression.
The mechanisms promoting cisplatin-sensitization of miR-30s include inhibition of EMT [36] , autophagy [31] , and other pro-chemoresistance molecules [54] . EMT is a dynamic process necessary for embryonic development and certain pathological events such as fibrosis and tumorigenesis [55] . Accumulating evidence indicates that EMT plays a pivotal role in metastasis and chemoresistance [56] . Snail is a well-known E-cadherintranscriptional repressor and EMT inducer that is significantly upregulated during EMT process [57] . We found Snail was targeted by miR-30a/c-5p acting as antagonists of EMT in the ovarian cancer cells. However, the role of miR-30s in EMT is controversial in that miR30a/c-5p can function either as antagonist [54, [58] [59] [60] [61] or agonist [62] of EMT, suggesting that miR-30s might be involved in different pathways via targeting different genes.
A better understanding of the molecular mechanisms underlying cisplatin-sensitivity is necessary for developing successful strategies to treat ovarian cancer. Our cell-based observations implicated miR-30a/c-5p as part of the regulatory signaling events involved in cellular response of ovarian cancer cells to cisplatin, thus underscoring a possible alternative therapeutic strategy for the treatment of cisplatin-resistant ovarian cancer patients.
Conclusions
MiR-30a/c-5p are aberrantly methylated and thus silenced by overexpressed DNMT1, which relieves the inhibitory effect of miR-30a/c-5p on DNMT1 and Snail, leading to cisplatin resistance and partial EMT in ovarian cancer. Our study implicates miR-30a/c-5p and DNMT1 as promising therapeutic targets for the treatment of cisplatin-refractory ovarian cancer and control of metastasis.
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